THERAPY DOSSIER · th-e4f141983e7a

Chicoric acid

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT05077813 ↗PHASE2unknown

Chicoric acid, 13-cis retinoic acid (aerosolized), minocycline and vitamin D as quadrate therapy for MDR-TB and MDR-TB/COVID-19

Tuberculosis

Enrolment: 250 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31989756 ↗2020Reported benefit

Chicoric acid ameliorate inflammation and oxidative stress in Lipopolysaccharide and d-galactosamine induced acute liver injury.

MouseEndotoxin/LPSC57BL/6Male12.5, 25 and 50 mg/kg in vivo (dissolved in 5% dimethyl sul…1 h before lipopolysaccharide and D-galactosamine challenge

Model: Acute liver injury and acute liver failure induced by lipopolysaccharide (30 ug/kg) plus D-galactosamine (600 mg/kg)

Chicoric acid reduced serum AST and ALT and lowered mortality after lipopolysaccharide and D-galactosamine challenge. It suppressed MAPK and NF-kappaB signalling, activated the Nrf2 pathway with increased AMPK, raised hepatic glutathione and reduced reactive oxygen species and myeloperoxidase, and…

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…